MIGRAINOUS INFARCTION: A CLINICAL REVIEW OF PATHOPHYSIOLOGY, DIAGNOSIS, AND MODERN THERAPEUTIC STRATEGIES
DOI:
https://doi.org/10.55640/Keywords:
Migrainous infarction; Migraine with aura; Ischemic stroke; Cortical spreading depression; CGRP-targeted therapy; Central Asia; Young stroke; Neurovascular dysfunction; Preventive treatment; Cerebrovascular risk.Abstract
Migraine represents one of the most prevalent neurological disorders globally and is increasingly recognized as a complex brain disease with significant cerebrovascular implications. Among its rare but severe complications, migrainous infarction constitutes a critical entity that bridges primary headache disorders and ischemic stroke. This narrative review examines the current understanding of migrainous infarction, with particular emphasis on epidemiological data from Central Asia, underlying pathophysiological mechanisms, diagnostic challenges, and emerging therapeutic approaches. The analysis reveals that Central Asian countries demonstrate a disproportionately high burden of both migraine and stroke, with Uzbekistan ranking among the top nations globally for age-standardized stroke incidence. The pathophysiology of migrainous infarction involves cortical spreading depression, neurovascular dysfunction, and prothrombotic changes, predominantly affecting young women with migraine with aura in the posterior circulation territory. Diagnosis remains challenging due to the necessity of excluding alternative stroke etiologies, particularly in young patients without traditional vascular risk factors. The advent of calcitonin gene-related peptide (CGRP)-targeted therapies represents a paradigm shift in migraine management, offering effective prevention without vasoconstrictive effects and demonstrating favorable cardiovascular safety profiles in recent large-scale studies. However, caution is warranted in patients with established cerebrovascular disease. The review underscores the importance of individualized risk assessment, comprehensive diagnostic evaluation, and integration of modern preventive strategies in clinical practice across Central Asia and globally.
Downloads
References
1. Headache Classification Committee of the International Headache Society. The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
2. The burden of migraine and tension-type headache in Asia from 1990 to 2021. The Journal of Headache and Pain. 2025. (GBD 2021 data for Central Asia)
3. Kilichev IA, Adambayev ZI, Matyokubov MO. Dynamics of some epidemiological indicators of stroke in the desert-steppe zones of Uzbekistan during the period of independence of the republic. Medical News. 2022;1:76-78.
4. Epidemiological trends and forecasts in stroke. Stroke Journal. 2025. (GBD 2021: Uzbekistan 4th globally in stroke incidence)
5. Eller MT, Schwarzova K, Gufler L, et al. CGRP-targeted migraine therapies in patients with vascular risk factors or stroke: a review. Neurology. 2025;105(2):e213852(1)-e213852(9).
6. American Headache Society. Position Statement: CGRP Inhibitors should now be considered a first-line option for migraine prevention. 2024.
7. Dodick DW, Tepper SJ, Ailani J, et al. Effect of erenumab versus other migraine preventive medications on cardiovascular and cerebrovascular outcomes: a United States claims database-based observational cohort study. Headache. 2025.
8. Chen SP, Ayata C. Migraine and stroke: an update. Current Opinion in Neurology. 2023;36(3):197-204.
Downloads
Published
Issue
Section
License

This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

Germany
United States of America
Italy
United Kingdom
France
Canada
Uzbekistan
Japan
Republic of Korea
Australia
Spain
Switzerland
Sweden
Netherlands
China
India